Which has preferable earnings & valuation, NBTX or BNTC?

Nanobiotix has higher revenue and earnings than Benitec Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 32.51 -$27.11M N/A N/A Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A

Is NBTX or BNTC more profitable?

Nanobiotix's return on equity of 0.00% beat Benitec Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Benitec Biopharma N/A -28.41% -27.76%

Does the media refer more to NBTX or BNTC?

In the previous week, Benitec Biopharma had 1 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for Benitec Biopharma and 2 mentions for Nanobiotix. Benitec Biopharma's average media sentiment score of 0.37 beat Nanobiotix's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Benitec Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, TYRA or BNTC?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A

Is TYRA or BNTC more profitable?

Benitec Biopharma's return on equity of -28.41% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -46.39% -43.07% Benitec Biopharma N/A -28.41% -27.76%

Does the media prefer TYRA or BNTC?

In the previous week, Tyra Biosciences had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for Tyra Biosciences and 3 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.37 beat Tyra Biosciences' score of 0.13 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Benitec Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, BNTC or DMRA?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A

Is BNTC or DMRA more profitable?

Benitec Biopharma's return on equity of -28.41% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -28.41% -27.76% Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86%

Does the media favor BNTC or DMRA?

In the previous week, Benitec Biopharma and Benitec Biopharma both had 3 articles in the media. Benitec Biopharma's average media sentiment score of 0.37 beat Damora Therapeutics, Inc. Common Stock's score of 0.10 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, BNTC or REPL?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$45.55M -$0.98 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is BNTC or REPL more profitable?

Benitec Biopharma's return on equity of -28.41% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -28.41% -27.76% Replimune Group N/A -159.32% -90.84%

Does the media prefer BNTC or REPL?

In the previous week, Benitec Biopharma and Benitec Biopharma both had 3 articles in the media. Replimune Group's average media sentiment score of 0.41 beat Benitec Biopharma's score of 0.37 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MNKD or BNTC?

In the previous week, MannKind had 7 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for MannKind and 3 mentions for Benitec Biopharma. MannKind's average media sentiment score of 0.53 beat Benitec Biopharma's score of 0.37 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Benitec Biopharma (BNTC) Competitors

$8.87 +0.12 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$8.86 -0.01 (-0.11%)

As of 07:30 PM Eastern

Compare

BNTC vs. NBTX, TYRA, DMRA, REPL, and MNKD

Should you buy Benitec Biopharma stock or one of its competitors? Benitec Biopharma's main competitors and comparable companies include Nanobiotix (NBTX), Tyra Biosciences (TYRA), Damora Therapeutics, Inc. Common Stock (DMRA), Replimune Group (REPL), and MannKind (MNKD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Benitec Biopharma compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Nanobiotix has higher revenue and earnings than Benitec Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	32.51	-$27.11M	N/A	N/A
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A

Nanobiotix currently has a consensus target price of $46.67, suggesting a potential upside of 97.07%. Benitec Biopharma has a consensus target price of $24.00, suggesting a potential upside of 170.57%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Nanobiotix's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Benitec Biopharma	N/A	-28.41%	-27.76%

In the previous week, Benitec Biopharma had 1 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for Benitec Biopharma and 2 mentions for Nanobiotix. Benitec Biopharma's average media sentiment score of 0.37 beat Nanobiotix's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Benitec Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nanobiotix has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Summary

Benitec Biopharma beats Nanobiotix on 7 of the 12 factors compared between the two stocks.

How does Benitec Biopharma compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Benitec Biopharma's return on equity of -28.41% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Benitec Biopharma	N/A	-28.41%	-27.76%

In the previous week, Tyra Biosciences had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for Tyra Biosciences and 3 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.37 beat Tyra Biosciences' score of 0.13 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Benitec Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Benitec Biopharma is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A

Tyra Biosciences presently has a consensus price target of $47.20, suggesting a potential upside of 136.71%. Benitec Biopharma has a consensus price target of $24.00, suggesting a potential upside of 170.57%. Given Benitec Biopharma's higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Tyra Biosciences beats Benitec Biopharma on 8 of the 14 factors compared between the two stocks.

How does Benitec Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Benitec Biopharma (NASDAQ:BNTC) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Benitec Biopharma and Benitec Biopharma both had 3 articles in the media. Benitec Biopharma's average media sentiment score of 0.37 beat Damora Therapeutics, Inc. Common Stock's score of 0.10 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Benitec Biopharma currently has a consensus price target of $24.00, indicating a potential upside of 170.57%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $46.50, indicating a potential upside of 120.59%. Given Benitec Biopharma's higher possible upside, research analysts plainly believe Benitec Biopharma is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Benitec Biopharma is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

Benitec Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Benitec Biopharma's return on equity of -28.41% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

Summary

Benitec Biopharma beats Damora Therapeutics, Inc. Common Stock on 8 of the 12 factors compared between the two stocks.

How does Benitec Biopharma compare to Replimune Group?

Benitec Biopharma (NASDAQ:BNTC) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Benitec Biopharma currently has a consensus target price of $24.00, indicating a potential upside of 170.57%. Replimune Group has a consensus target price of $12.00, indicating a potential downside of 10.58%. Given Benitec Biopharma's higher possible upside, research analysts clearly believe Benitec Biopharma is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Benitec Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Benitec Biopharma is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Benitec Biopharma's return on equity of -28.41% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
Replimune Group	N/A	-159.32%	-90.84%

In the previous week, Benitec Biopharma and Benitec Biopharma both had 3 articles in the media. Replimune Group's average media sentiment score of 0.41 beat Benitec Biopharma's score of 0.37 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 5.4% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Benitec Biopharma and Replimune Group tied by winning 6 of the 12 factors compared between the two stocks.

How does Benitec Biopharma compare to MannKind?

MannKind (NASDAQ:MNKD) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

MannKind presently has a consensus price target of $7.84, indicating a potential upside of 138.41%. Benitec Biopharma has a consensus price target of $24.00, indicating a potential upside of 170.57%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

MannKind has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

MannKind has higher revenue and earnings than Benitec Biopharma. MannKind is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.03	$5.86M	-$0.13	N/A
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A

Benitec Biopharma has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	N/A	-6.31%
Benitec Biopharma	N/A	-28.41%	-27.76%

In the previous week, MannKind had 7 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for MannKind and 3 mentions for Benitec Biopharma. MannKind's average media sentiment score of 0.53 beat Benitec Biopharma's score of 0.37 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

49.6% of MannKind shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MannKind beats Benitec Biopharma on 8 of the 13 factors compared between the two stocks.

Get Benitec Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTC vs. The Competition

Export

Metric	Benitec Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$305.22M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	20.71%
P/E Ratio	-9.05	13.42	274.13	26.16
Price / Sales	N/A	1,237.44	589.97	95.24
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	1.72	17.17	11.21	6.34
Net Income	-$45.55M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-1.22%	-1.20%	-0.84%	-1.39%
1 Month Performance	-28.76%	-9.68%	-5.42%	-4.31%
1 Year Performance	-37.54%	10.09%	4.38%	-0.35%

Benitec Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTC Benitec Biopharma	2.5262 of 5 stars	$8.87 +1.4%	$24.00 +170.6%	-37.9%	$305.22M	N/A	N/A	24	Analyst Forecast
NBTX Nanobiotix	2.7014 of 5 stars	$25.23 +0.5%	$46.67 +85.0%	-16.1%	$1.27B	$36.87M	N/A	97	Gap Up
TYRA Tyra Biosciences	3.356 of 5 stars	$20.24 -3.3%	$47.20 +133.2%	+46.5%	$1.25B	N/A	N/A	87	Analyst Forecast
DMRA Damora Therapeutics, Inc. Common Stock	3.037 of 5 stars	$19.55 -3.3%	$46.50 +137.9%	+93.1%	$1.25B	N/A	N/A	40
REPL Replimune Group	1.2412 of 5 stars	$13.25 +0.8%	$12.00 -9.4%	+185.3%	$1.23B	N/A	N/A	465

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTC) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Benitec Biopharma (BNTC) Competitors

BNTC vs. NBTX, TYRA, DMRA, REPL, and MNKD

How does Benitec Biopharma compare to Nanobiotix?

Summary

How does Benitec Biopharma compare to Tyra Biosciences?

Summary

How does Benitec Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Benitec Biopharma compare to Replimune Group?

Summary

How does Benitec Biopharma compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Benitec Biopharma (BNTC) Competitors

BNTC vs. NBTX, TYRA, DMRA, REPL, and MNKD

How does Benitec Biopharma compare to Nanobiotix?

Which has preferable earnings & valuation, NBTX or BNTC?

Do analysts rate NBTX or BNTC?

Is NBTX or BNTC more profitable?

Does the media refer more to NBTX or BNTC?

Do insiders & institutionals have more ownership in NBTX or BNTC?

Which has more volatility & risk, NBTX or BNTC?

Summary

How does Benitec Biopharma compare to Tyra Biosciences?

Do insiders and institutionals have more ownership in TYRA or BNTC?

Is TYRA or BNTC more profitable?

Does the media prefer TYRA or BNTC?

Which has more risk and volatility, TYRA or BNTC?

Which has stronger earnings and valuation, TYRA or BNTC?

Do analysts rate TYRA or BNTC?

Summary

How does Benitec Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Does the media favor BNTC or DMRA?

Do analysts prefer BNTC or DMRA?

Which has higher earnings & valuation, BNTC or DMRA?

Which has more risk and volatility, BNTC or DMRA?

Do insiders & institutionals believe in BNTC or DMRA?

Is BNTC or DMRA more profitable?

Summary

How does Benitec Biopharma compare to Replimune Group?

Do analysts rate BNTC or REPL?

Which has more volatility & risk, BNTC or REPL?

Which has preferable earnings and valuation, BNTC or REPL?

Is BNTC or REPL more profitable?

Does the media prefer BNTC or REPL?

Do insiders and institutionals believe in BNTC or REPL?

Summary

How does Benitec Biopharma compare to MannKind?

Do analysts rate MNKD or BNTC?

Which has more risk and volatility, MNKD or BNTC?

Which has better earnings & valuation, MNKD or BNTC?

Is MNKD or BNTC more profitable?

Does the media refer more to MNKD or BNTC?

Do institutionals & insiders have more ownership in MNKD or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools